Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Agios Pharmaceuticals (AGIO) EPS (Basic) (2016 - 2025)

Historic EPS (Basic) for Agios Pharmaceuticals (AGIO) over the last 14 years, with Q3 2025 value amounting to -$1.78.

  • Agios Pharmaceuticals' EPS (Basic) fell 11069.07% to -$1.78 in Q3 2025 from the same period last year, while for Sep 2025 it was -$6.98, marking a year-over-year decrease of 15920.27%. This contributed to the annual value of $11.86 for FY2024, which is 28735.87% up from last year.
  • As of Q3 2025, Agios Pharmaceuticals' EPS (Basic) stood at -$1.78, which was down 11069.07% from -$1.93 recorded in Q2 2025.
  • In the past 5 years, Agios Pharmaceuticals' EPS (Basic) ranged from a high of $26.95 in Q1 2021 and a low of -$1.93 during Q2 2025
  • For the 5-year period, Agios Pharmaceuticals' EPS (Basic) averaged around $1.05, with its median value being -$1.55 (2025).
  • Its EPS (Basic) has fluctuated over the past 5 years, first soared by 229105.69% in 2021, then tumbled by 35671.64% in 2023.
  • Agios Pharmaceuticals' EPS (Basic) (Quarter) stood at $0.07 in 2021, then soared by 923.5% to $0.67 in 2022, then plummeted by 356.72% to -$1.72 in 2023, then increased by 1.21% to -$1.7 in 2024, then decreased by 4.76% to -$1.78 in 2025.
  • Its EPS (Basic) stands at -$1.78 for Q3 2025, versus -$1.93 for Q2 2025 and -$1.55 for Q1 2025.